{"id":976621,"date":"2026-06-29T11:05:44","date_gmt":"2026-06-29T15:05:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/"},"modified":"2026-06-29T11:05:44","modified_gmt":"2026-06-29T15:05:44","slug":"emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/","title":{"rendered":"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government"},"content":{"rendered":"
\n

GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000\u00ae <\/sup>(Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month.<\/p>\n

\u201cThis new contract modification for ACAM2000\u00ae<\/sup> underscores the U.S. government\u2019s continued focus on biodefense preparedness and reflects Emergent\u2019s longstanding role to collaborate and help protect civilians and warfighters against potential smallpox and mpox threats,\u201d said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. \u201cIn this increasingly dangerous world, we are proud to continue supporting the U.S. government as they continue to take critical, proactive steps on biodefense preparedness.\u201d<\/p>\n

This award follows Emergent\u2019s recent announcements that the Saudi Food and Drug Authority has approved ACAM2000\u00ae<\/a> for immunization against smallpox and mpox in high-risk individuals and that Singapore\u2019s Health Sciences Authority has approved an expanded indication for ACAM2000\u00ae<\/sup><\/a> to include prevention of mpox disease in adults determined to be at high risk for mpox infection.<\/p>\n

Experts consider smallpox to be a credible bioterror threat,\u00a0 with potential health, economic and national security implications due to its mortality rate.1\u00a0 <\/sup>Emergent specializes in developing, manufacturing and delivering medical countermeasures to the U.S. government and allies around the world to support health preparedness and help protect the public from potential threats like smallpox, mpox, Ebola, anthrax and botulism.<\/p>\n

This contract modification is under Emergent\u2019s existing 10-year contract (75A50119C00071) with ASPR.<\/p>\n

\n Indication and Select Important Safety Information for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live)<\/strong>
\n
\n Indication<\/strong>
\n
ACAM2000\u00ae is indicated for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.<\/p>\n

\n Important Safety Information <\/strong>
\n
\n Warning: Serious Complications <\/strong>
\n
Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia) which can cause ocular complications that may lead to blindness, and fetal death, have occurred following either primary vaccination or revaccination with ACAM2000\u00ae<\/strong> or other live vaccinia virus vaccines that were used historically.<\/p>\n

\n Contraindications<\/u>
\n
Do not administer ACAM2000\u00ae<\/strong> to individuals with severe immunodeficiency. These individuals may include persons who are undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation.<\/p>\n

\n Warnings and Precautions<\/u>
\n
Serious complications that may follow either primary or revaccination with ACAM2000\u00ae<\/strong> include myocarditis and\/or pericarditis, ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum, fetal vaccinia, fetal death, and accidental eye infection (ocular vaccinia) that may lead to blindness. ACAM2000\u00ae<\/strong> is a live vaccinia virus that can be transmitted to persons who have close contact with the vaccinee and the risks in contacts are the same as those stated for vaccinees.<\/p>\n

\n Adverse Reactions<\/u>
\n
Common adverse reactions include inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache.
To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or medicalinformation@ebsi.com<\/a>; or VAERS at 1-800-822-7967 or https:\/\/vaers.hhs.gov<\/a>.<\/p>\n

Please see the full Prescribing Information<\/a> for ACAM2000\u00ae<\/strong> for complete Boxed Warning and safety information.<\/p>\n

\n About\u00a0Emergent BioSolutions<\/strong>
\n
At Emergent, our mission is to protect and save lives.\u00a0For over 25 years,\u00a0we\u2019ve\u00a0been at work preparing those entrusted with protecting public health.\u00a0We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola,\u00a0anthrax\u00a0and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today\u2019s health challenges and tomorrow\u2019s threats, visit our\u00a0website<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>,\u00a0X<\/a>,\u00a0Instagram<\/a>,\u00a0Apple Podcasts<\/a>\u00a0and\u00a0Spotify<\/a>.\u00a0<\/p>\n

\n Safe Harbor Statement<\/strong>\u00a0
This\u00a0press\u00a0release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact,\u00a0including statements regarding the expected timing for delivery of the ACAM2000\u00ae <\/strong>vaccine, are forward-looking\u00a0statements.\u00a0We generally identify forward-looking statements by using words like \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cfuture,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cposition,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be\u00a0accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect\u00a0new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors\u00a0identified\u00a0in our periodic reports filed with the\u00a0U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.\u00a0<\/p>\n

\n Investor Contact:<\/strong>
\n
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com<\/a><\/p>\n

\n 1<\/sup>
\n Smallpox as a Weapon for Bioterrorism<\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month. \u201cThis new contract modification for ACAM2000\u00ae underscores the U.S. government\u2019s continued focus on biodefense preparedness and reflects Emergent\u2019s longstanding role to collaborate and help protect civilians and warfighters against potential smallpox and mpox threats,\u201d said Paul Williams, senior vice president, head of products business, global government & … <\/p>\n

Continue reading “Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-976621","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEmergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month. \u201cThis new contract modification for ACAM2000\u00ae underscores the U.S. government\u2019s continued focus on biodefense preparedness and reflects Emergent\u2019s longstanding role to collaborate and help protect civilians and warfighters against potential smallpox and mpox threats,\u201d said Paul Williams, senior vice president, head of products business, global government & … Continue reading "Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T15:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government\",\"datePublished\":\"2026-06-29T15:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/\"},\"wordCount\":968,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/\",\"name\":\"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=\",\"datePublished\":\"2026-06-29T15:05:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/","og_locale":"en_US","og_type":"article","og_title":"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government - Market Newsdesk","og_description":"GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month. \u201cThis new contract modification for ACAM2000\u00ae underscores the U.S. government\u2019s continued focus on biodefense preparedness and reflects Emergent\u2019s longstanding role to collaborate and help protect civilians and warfighters against potential smallpox and mpox threats,\u201d said Paul Williams, senior vice president, head of products business, global government & … Continue reading \"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-29T15:05:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government","datePublished":"2026-06-29T15:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/"},"wordCount":968,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/","name":"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=","datePublished":"2026-06-29T15:05:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1NDAyNyM3NjgxOTE4IzIwMTA4NjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-secures-contract-modification-valued-at-approximately-52-7-million-for-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-from-the-u-s-government\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000\u00ae (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=976621"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976621\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=976621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=976621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=976621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}